Clinical trial
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
NCT02278315 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Cellectar Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2015
- Completion date
- August 10, 2022
- Enrollment
- 31 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.